Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)
Accession Number
DB11044
Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Inactivated
Description

A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.

There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.

Synonyms
Not Available
Active Moieties
NameKindUNIICASInChI Key
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)hemagglutinin45E2IPU4MGNot AvailableNot applicable
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AfluriaInfluenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) (7.5 ug/0.25mL) + Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) (7.5 ug/0.25mL) + Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) (7.5 ug/0.25mL)Injection, suspensionIntramuscularCsl Limited2009-07-012010-06-30Us
AfluriaInfluenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularCsl Limited2009-07-012010-06-30Us
AfluriaInfluenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Hong Kong/4801/2014 X-263B (H3N2) antigen (propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularSeqirus Pty Ltd2011-07-152016-06-17Us
AfluriaInfluenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Hong Kong/4801/2014 X-263B (H3N2) antigen (propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularSeqirus Pty Ltd2011-07-152016-06-17Us
AfluriaInfluenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularCsl Limited2011-07-152012-06-30Us
AfluriaInfluenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularCsl Limited2011-07-152012-06-30Us
AfluriaInfluenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularCsl Limited2010-07-302011-06-30Us
AfluriaInfluenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularCsl Limited2010-07-302011-06-30Us
FluvirinInfluenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Hong Kong/4801/2014 X-263B (H3N2) antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Singapore/gp1908/2015 IVR-180 (H1N1) antigen (propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularCatalent Belgium Sa2017-07-012018-06-30Us
FluvirinInfluenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Hong Kong/4801/2014 X-263B (H3N2) antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Singapore/gp1908/2015 IVR-180 (H1N1) antigen (propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularSeqirus Inc.2017-07-012018-06-30Us
Categories
UNII
293LSV29OL
CAS number
Not Available

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
2-MethoxyethanolThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin AThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Abatacept.
AbetimusThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Abetimus.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) is combined with Acetylsalicylic acid.
ActeosideThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Acteoside.
AdalimumabThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Adalimumab.
AfelimomabThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Afelimomab.
AldesleukinThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Aldesleukin.
AldosteroneThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Aldosterone.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2CompletedPreventionEgg Allergy / Eligible for Vaccination Against Influenza1
3CompletedPreventionFlu caused by Influenza2
4CompletedPreventionFlu caused by Influenza1
4CompletedPreventionInfluenza, Human3
4Enrolling by InvitationTreatmentInfertility1
4Enrolling by InvitationTreatmentInfertility / Recurrent Miscarriages1
Not AvailableCompletedNot AvailableInflammatory Bowel Diseases (IBD)1
Not AvailableCompletedBasic ScienceImmune Response1
Not AvailableRecruitingNot AvailableFetal Malformation / Influenza, Human / Pregnancy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, suspensionIntramuscular
KitTopical
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on December 01, 2015 13:05 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates